Checkpoint Inhibitors for Treating Cancer Market Major Players Analysis and Forecast 2018-2023 | AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech (Checkpoint Therapeutics)

In this report, the present scenario (with the base year being 2017) and the growth prospects of global Checkpoint Inhibitors for Treating Cancer market for 2018-2023.

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Get Easy Access to Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-112856

Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.

Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.

Over the next five years, Checkpoint Inhibitors for Treating Cancer will register a 28.0% CAGR in terms of revenue, reach US$ 20600 million by 2023, from US$ 4690 million in 2017.

Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-112856

This report presents a comprehensive overview, market shares, and growth opportunities of Checkpoint Inhibitors for Treating Cancer market by product type, application, key manufacturers and key regions.

To calculate the market size, we considers value and volume generated from the sales of the following segments:

Segmentation by product type:
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors

Segmentation by application:
Melanoma Treatment
Bladder Cancer Treatment
Other

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences)
Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Immutep Limited
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
Novartis AG
Pfizer Inc.

Purchase Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-112856/

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Checkpoint Inhibitors for Treating Cancer consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Checkpoint Inhibitors for Treating Cancer market by identifying its various subsegments.
Focuses on the key global Checkpoint Inhibitors for Treating Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Checkpoint Inhibitors for Treating Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Checkpoint Inhibitors for Treating Cancer submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
IN +919881074592
info@qurateresearch.com
https://www.qurateresearch.com/

This release was published on openPR.